Compare Abeona Therapeutics Inc (ABEO) vs Diamondback Energy Inc (FANG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Diamondback Energy Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Diamondback Energy Inc trades at $186.69 (market cap $50.79B). The key difference: Diamondback Energy Inc is far larger — about 136× Abeona Therapeutics Inc's market cap, and Diamondback Energy Inc pays a 2.44% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | FANG | |
|---|---|---|
Market Cap | $373.32M | $50.79B |
Sector | Health | Energy |
52-Week High | $7.23 | $213.69 |
52-Week Low | $4.17 | $134.53 |
Enterprise Value | $228.22M | $64.52B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Diamondback Energy (FANG) trades at $180.56, up 4.95% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth to $14.93B in 2025 but faces declining net margins. Analyst consensus is overwhelmingly bullish with a $232.10 price target, supported by positive energy sector sentiment from Zacks and Seeking Alpha as of late June 2026.
FANG offers upside potential from high analyst targets and operational cash flow strength, but risks include volatile oil prices, margin compression, and technical resistance near $175. The stock's high P/E of 177.28 reflects growth expectations, yet execution on Q2 2026 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →
